| A737 |
Leronlimab
Featured
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer. |
|
| A738 |
Atibuclimab
Featured
|
Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. |
|
| A739 |
Pierre Fabre patent anti-CD151
Featured
|
|
|
| A740 |
Anti-CD163 Antibody (OR2805)
Featured
|
|
|
| A741 |
Tafasitamab
Featured
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19. |
|
| A742 |
Inebilizumab
Featured
|
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. |
|
| DC67117 |
113-N16B
Featured
|
113-N16B is an ionizable cationic lipid used for the generation of lipid nanoparticles (LNPs). 113-N16B delivers mRNA preferentially to pulmonary endothelial cells. |
|
| DC67120 |
YSK12-C4 (YSK12-MEND)
Featured
|
YSK 12C4 is an ionizable cationic lipid primarily used to enhance siRNA cellular delivery via multifunctional envelope-type nanodevices (MEND). YSK 12C4 promotes siRNA uptake and endosomal escape, effectively silencing genes in human immune cell lines. |
|
| DC67124 |
Cho-Arg TFA |
Cho-Arg TFA is a steroid-based cationic lipid with an L-Arginine headgroup. Cho-Arg TFA shows a remarkably high optimized plasmid DNA transfection efficacy. |
|
| DC67126 |
80-O18
Featured
|
80-O18 is a lipidoid known for its exceptional ability to enhance overall cellular uptake, showcasing significant potential as an effective delivery agent. |
|
| DC67128 |
Lipid 29 analogue-2
Featured
|
Lipid 29 analogue-2 is an ionizable lipid designed for the delivery of RNA-based therapeutics, such as mRNA or siRNA. |
|
| DC67132 |
C16 PEG750 Ceramide |
C16 PEG750 Ceramide (C16 PEG Ceramide (MW 750)) is a PEG lipid for the preparation of liposomes and can be used in drug delivery studies. |
|
| A743 |
Loncastuximab
Featured
|
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). |
|
| A744 |
Denintuzumab
Featured
|
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia. |
|
| A745 |
Obexelimab
Featured
|
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus. |
|
| A746 |
Coltuximab
Featured
|
|
|
| A747 |
Duke U. patent anti-CD19
Featured
|
|
|
| A748 |
Immunomedics hA19
Featured
|
|
|
| A749 |
Siplizumab
Featured
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. |
|
| A750 |
TRU-015
Featured
|
|
|
| A751 |
Ripertamab
Featured
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL). |
|
| A752 |
Ublituximab
Featured
|
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects. |
|
| A753 |
Zuberitamab
Featured
|
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma. |
|
| A754 |
Veltuzumab
Featured
|
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL). |
|
| A755 |
Obinutuzumab
Featured
|
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma. |
|
| A756 |
Ocaratuzumab
Featured
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
| A757 |
Divozilimab
Featured
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research. |
|
| DC67136 |
SARM1-IN-2
Featured
|
SARM1-IN-2 (Example 82) is a SARM1 inhibitor with an IC50 value of <1 μM. SARM1-IN-2 inhibits axonal regrowth, leading to only 6% regrowth after 72 h of exposure. SARM1-IN-2 can be used for the research of axonal degeneration. |
|
| DC67137 |
SARM1-IN-3
Featured
|
SARM1-IN-3 (Example 30) is a SARM1 inhibitor. SARM1-IN-3 can be used in the study of chemotherapy induced peripheral neuropathy (CIPN). |
|
| DC67138 |
SARM1 Human Pre-designed siRNA Set A
Featured
|
SARM1 Human Pre-designed siRNA Set A contains three designed siRNAs for SARM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. |
|
